EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%-3-year update

Kilickap, S.Ozguroglu, M.Sezer, A.Gumus, M.Bondarenko, I.Gogishvili, M.Turk, H. M.2024-06-122024-06-1220231556-08641556-1380https://hdl.handle.net/20.500.14551/26773[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%-3-year updateConference Object184S42S43N/AWOS:000995007600011